Contact Ian

Speaking Engagements

  

There has been growing interest in targeting kinases such as JAK, TYK, IRAK, SIK, CDK, MEK, ERK, RTK, PLK, PI3K, ALK, MAPK, GSK, LRRK, and more for their role in neurodegeneration, inflammation, cancer, autoimmune, and other disorders. However, targeting kinases selectively and specifically has always been a challenge, as they intersect so many pat

25-25 September 2023
  

As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs and the po

26-27 September 2023